Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VICI Properties Inc (VICI) vs Zoetis Inc (ZTS) Price & Performance

VICI Properties IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

VICI Properties Inc vs Zoetis Inc — how do they compare? VICI Properties Inc trades at $22.89 (market cap $25.09B), while Zoetis Inc trades at $74.42 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and VICI Properties Inc pays the higher dividend (8.07%). Which is the better fit depends on your goals — on Pluang, investors hold VICI Properties Inc for 43 Days and Zoetis Inc for 70 Days on average.

VICIZTS
Market Cap
$25.09B$30.20B
Volume
17,066,3376,175,327
Sector
Real EstateHealth
52-Week High
$31.42$147.53
52-Week Low
$22.53$69.09
Typical Hold Time
43 Days70 Days
Enterprise Value
$42.65B$37.76B
Dividend Yield
8.07%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VICI Properties Inc

VICI Properties trades at $22.88, down 1.06% with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and attractive valuation at 8.83 P/E. The stock shows mixed earnings performance with recent misses but maintains robust cash flow and dividend coverage. Recent news highlights tenant diversification through new leases while addressing market concerns about regional casino exposure and rising interest rates.

The investment case balances deep value metrics against sector headwinds, with analyst consensus strongly bullish ($28.90 target) but technical weakness suggesting near-term pressure. Key opportunities include the 7.8% dividend yield with 1.3x coverage, while risks center on tenant concentration and interest rate sensitivity in the REIT structure.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VICI
100% Buy0% Sell
Avg holding period · 43 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About VICI Properties Inc

VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.

Read more on VICI →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →